Veozah vs Lynkuet: how the two non-hormonal hot flash pills compare
The short answer
Veozah (fezolinetant) and Lynkuet (elinzanetant) are both daily non-hormonal pills for moderate to severe hot flashes due to menopause. Veozah blocks one brain receptor (NK3); Lynkuet blocks two (NK1 and NK3) and is taken at bedtime. The biggest practical differences are safety: Veozah carries a boxed warning for rare but serious liver injury and needs regular liver tests for the first nine months, while Lynkuet needs liver tests at the start and at 3 months and can cause daytime sleepiness. We're not telling you which to take; that is a decision for you and your clinician.
For years, women who couldn't or didn't want to take hormones had few good prescription options for hot flashes. Now there are two pills in a brand-new class, approved about two and a half years apart. They sound alike and work in similar ways, but they are not interchangeable. Here is what the FDA labels actually say.
Veozah vs Lynkuet at a glance
| Veozah (fezolinetant) | Lynkuet (elinzanetant) | |
|---|---|---|
| FDA approval | May 12, 2023 | October 24, 2025 |
| How it works | Blocks the NK3 receptor in the brain's temperature-control center | Blocks both NK1 and NK3 receptors |
| Approved for | Moderate to severe hot flashes and night sweats due to menopause | Moderate to severe hot flashes and night sweats due to menopause |
| How it's taken | Tablet once a day, at about the same time each day, with or without food | Capsules once a day at bedtime, with or without food, swallowed whole |
| Boxed warning | Yes: rare but serious liver injury | No |
| Liver blood tests | Before starting, monthly for the first 3 months, then at months 6 and 9 | Before starting and at 3 months |
| Other key warnings | Liver injury is the label's main warning | Drowsiness and daytime impairment; caution with a seizure history; can cause pregnancy loss |
| Not for you if | You have cirrhosis, severe kidney disease or kidney failure, or take a medicine that blocks the CYP1A2 liver enzyme | You are pregnant. Not recommended with moderate or severe liver disease, and many medicines that affect the CYP3A4 enzyme (and grapefruit) need to be avoided or adjusted |
| Most common side effects | Abdominal pain, diarrhea, trouble sleeping, back pain, hot flush, raised liver enzymes | Headache, fatigue, dizziness, sleepiness |
How they work
Both act on brain cells involved in temperature control, called KNDy neurons, by blocking neurokinin receptors on them. Veozah, the first drug of its kind, blocks the NK3 receptor. Lynkuet blocks NK3 and also NK1, which makes it the first dual neurokinin blocker. Neither contains hormones.
Veozah: the liver warning
In September 2024 the FDA warned about rare but serious liver injury in people taking Veozah, and in December 2024 it upgraded that to a boxed warning, its most prominent kind. The label now calls for liver blood tests before you start, monthly for the first three months, and then at months 6 and 9.
The FDA tells patients to stop Veozah right away and contact the prescriber if they notice signs of liver trouble: unusual tiredness, nausea or vomiting, unusual itching, light-colored stools, yellowing of the skin or eyes, dark urine, abdominal swelling, or pain in the upper right belly.
Veozah also can't be taken with medicines that block the CYP1A2 enzyme, such as the antidepressant fluvoxamine, because they raise Veozah levels in the blood. Bring your full medication list.
Lynkuet: drowsiness, liver tests and pregnancy
Lynkuet is taken at bedtime for a reason: sleepiness and related nervous system effects were more common than with placebo in trials. The label advises not driving or doing anything hazardous until you know how it affects you. Liver blood tests are needed before you start and again at 3 months, and you should stop it and call your clinician if you develop symptoms of liver injury.
Lynkuet must not be used in pregnancy. The label says to rule out pregnancy before starting and to use effective contraception during treatment and for 2 weeks after stopping. That matters more than it sounds: you can still get pregnant in perimenopause, until you have gone a full year without a period. Lynkuet is broken down by the CYP3A4 enzyme, so strong blockers of that enzyme and grapefruit should be avoided, and some other medicines change the dose or rule it out. It should also be used with caution in anyone with a history of seizures.
Which works better?
As of today, we found no head-to-head trial comparing them directly. One 2025 indirect analysis, which compared results across separate trials, concluded they had a similar effect on how often and how severely hot flashes happen. Indirect comparisons are useful but can't replace a direct trial.
In practice, the choice often comes down to your other medicines, your liver and kidney health, how you feel about frequent blood tests versus possible drowsiness, and what your insurance covers. Some clinicians are interested in whether Lynkuet's extra NK1 action helps with sleep, and some have flagged its large capsule size as a hassle for women who have trouble swallowing pills. Neither of those should decide it for you without a conversation.
Want the full plan? Our guide lays out every hot flash option, hormonal and non-hormonal, side by side, with the questions to ask before you start anything. The Sisu Season Guide is $27 for founding readers until November 15, then $37.
How they compare with hormone therapy
The Menopause Society calls hormone therapy the most effective treatment for hot flashes, and for healthy women under 60 or within 10 years of menopause without contraindications, it concludes the benefits outweigh the risks. Hormone therapy also treats vaginal dryness and helps prevent bone loss. Veozah and Lynkuet are approved only for hot flashes and night sweats. The Menopause Society's 2023 nonhormone review recommended fezolinetant based on strong evidence; Lynkuet was approved after that review.
That makes these pills an important option for women who can't take estrogen or would rather not. Neither is currently FDA-approved specifically for hot flashes caused by breast cancer treatment. Bayer has asked the FDA to add that use for Lynkuet, and the FDA accepted the application for Priority Review in September 2026. Read more in what changed with HRT in 2025 and hot flash relief without hormones.
Questions to bring to your clinician
- Given my liver, kidneys and medication list, is either one safe for me?
- Who orders my liver tests, and how will I get the results?
- If I am still having periods, what contraception do I need?
- How will we know it is working, and when do we reassess?
- How does this compare with hormone therapy for someone with my history?
Tracking how many hot flashes you have, and how much they disrupt sleep, makes this conversation far more productive. Our free Symptom Snapshot builds a one-page summary in three minutes, and our doctor visit playbook covers the rest. If night sweats are wrecking your sleep, see waking at 3am in perimenopause.
Red flags
- On either drug: yellow skin or eyes, dark urine, pale stools, itching, nausea, or pain in the upper right belly. Stop the medicine and call your prescriber right away.
- On Lynkuet: feeling too drowsy to drive or work safely. Don't drive, and tell your clinician.
- A seizure, chest pain or trouble breathing: call 911.
Questions
Is Lynkuet better than Veozah?
There is no head-to-head trial. One 2025 indirect analysis found similar effects on hot flash frequency and severity. They differ mainly in safety monitoring and side effects: Veozah has a boxed liver warning with more frequent liver tests, while Lynkuet can cause drowsiness and must not be used in pregnancy. Your clinician can help weigh them for your history.
Can I take Veozah or Lynkuet if I've had breast cancer?
Neither is currently FDA-approved specifically for hot flashes caused by breast cancer treatment. Bayer has applied to add that use for Lynkuet, and the FDA accepted the application for Priority Review in September 2026. Talk with your oncology team before starting any hot flash treatment.
How often do you need liver tests on Veozah?
According to the current label, before you start, monthly for the first three months, and then at months 6 and 9, plus any time you have symptoms of liver injury. Lynkuet requires liver tests before starting and at 3 months.
Get the whole picture in one place
The Sisu Season Guide: every symptom decoded, every option explained, and exactly what to say at your appointment. Instant download. $27 until November 15, $37 after. 30-day money-back guarantee.
Not ready? Start with the free Symptom Snapshot.
Keep reading
- Perimenopause symptoms: the full list and red flags
- Am I in perimenopause? The stages, explained
- What changed with HRT after the FDA label change
- Hot flash relief without hormones
- How to talk to your doctor about menopause
- Perimenopause anxiety: why it can start out of nowhere, and what helps
- Waking up at 3am in perimenopause? Here's why, and what helps
- Perimenopause weight gain: why your body is changing, and what actually helps
Education and personal experience, not medical advice. Talk with your own clinician before making health decisions.
Sources
- FDA approves novel drug to treat moderate to severe hot flashes caused by menopause (FDA, May 12, 2023)
- FDA adds warning about rare occurrence of serious liver injury with Veozah (FDA Drug Safety Communication)
- Veozah (fezolinetant) prescribing information (Drugs.com)
- Lynkuet (elinzanetant) prescribing information (FDA)
- Lynkuet (elinzanetant) prescribing information (Drugs.com)
- Bayer: Lynkuet receives FDA approval (Oct 24, 2025)
- Bayer: FDA accepts supplemental application for Lynkuet in women on breast cancer endocrine therapy (Sept 2026)
- Fezolinetant compared with elinzanetant: a matching-adjusted indirect comparison (Maturitas, 2025)
- Two new tools for hot flashes: a clinical comparison of NK receptor antagonists (Pharmacy Times)
- Cleveland Clinic: Can you get pregnant during perimenopause?
- The Menopause Society, 2022 Hormone Therapy Position Statement (PubMed)
- The Menopause Society, 2023 Nonhormone Therapy Position Statement (Guideline Central summary)
- Recommendations updated for nonhormonal management of hot flashes (HealthDay via Drugs.com, June 2023)